Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[89Zr]-Df-CriPec Docetaxel PET Study in Solid Tumors
NCT03712423Phase 1Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in solid tumor, sponsored by Amsterdam University Medical Center. Primary endpoints: Visual detection of [89Zr]-Df-CriPec docetaxel in tumor lesions at 14 days and Quantitative detection of [89Zr]-Df-CriPec docetaxel in tumor lesions at 14 days. Started Apr 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03712423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712423.